A compound of Formula Ii, Ij, Il or Im: or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, wherein: R 1 is selected from Br, Cl, I, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -NR 3 R 4 , and -OR 5 ; R 2 is selected from H, F, Cl, C 1 -C 6 alkyl, and -O(C 1 -C 6 alkyl); R 3 is selected from H, and C 1 -C 6 alkyl; R 4 is selected from H, C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; or R 3 and R 4 form a 4-membered, 5-membered or 6-membered heterocyclyl ring; R 5 is selected from C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; A is selected from C 6 -C 20 aryl, -(C 6 -C 20 aryl)-(C 6 -C 20 aryl), -(C 6 -C 20 aryl)-(C 1 -C 20 heteroaryl), -(C 6 -C 20 aryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 1 -C 20 heteroaryl), C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; and where alkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , C(CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 OH, -CH 2 OCH 3 , -CH 2 CH 2 OH, -C(CH 3 ) 2 OH, -CH(OH)CH(CH 3 ) 2 , -C(CH 3 ) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3 , -CH 2 OP(O)(OH) 2 , -CH 2 F, -CHF 2 , -CH 2 NH 2 , -CH 2 NHSO 2 CH 3 , -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , -CF 3 , -CH 2 CF 3 , -CH 2 CHF 2 , -CH(CH 3 )CN, -C(CH 3 ) 2 CN, -CH 2 CN, -CO 2 H, -COCH 3 , -CO 2 CH 3 , -CO 2 C(CH 3 ) 3 , -COCH(OH)CH 3 , -CONH 2 , -CONHCH 3 , -CONHCH 2 CH 3 , -CONHCH(CH 3 ) 2 , -CON(CH 3 ) 2 , -C(CH 3 ) 2 CONH 2 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NHCOCH 3 , -N(CH 3 )COCH 3 , -NHS(O) 2 CH 3 , -N(CH 3 )C(CH 3 ) 2 CONH 2 , -N(CH 3 )CH 2 CH 2 S(O) 2 CH 3 , -NO 2 , =O, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OCH 3 , -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3 ) 2 , -OP(O)(OH) 2 , -S(O) 2 N(CH 3 ) 2 , -SCH 3 , -S(O) 2 CH 3 , -S(O) 3 H, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, cyclopentyl, tetrahydrofuranyl, morpholinyl, piperidyl, piperazinyl, and tetrahydropyranyl. R 1 is selected from Br, Cl, I, C 2 -C 20 heterocyclyl, C 1 -C 20 heteroaryl, -NR 3 R 4 , and -OR 5 ; R 2 is selected from H, F, Cl, C 1 -C 6 alkyl, and -O(C 1 -C 6 alkyl); R 3 is selected from H, and C 1 -C 6 alkyl; R 4 is selected from H, C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; or R 3 and R 4 form a 4-membered, 5-membered or 6-membered heterocyclyl ring; R 5 is selected from C 1 -C 6 alkyl, C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; A is selected from C 6 -C 20 aryl, -(C 6 -C 20 aryl)-(C 6 -C 20 aryl), -(C 6 -C 20 aryl)-(C 1 -C 20 heteroaryl), -(C 6 -C 20 aryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 2 -C 20 heterocyclyl), -(C 1 -C 20 heteroaryl)-(C 1 -C 20 heteroaryl), C 2 -C 20 heterocyclyl, and C 1 -C 20 heteroaryl; and where alkyl, aryl, heterocyclyl and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, -CN, -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , C(CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , -CH 2 OH, -CH 2 OCH 3 , -CH 2 CH 2 OH, -C(CH 3 ) 2 OH, -CH(OH)CH(CH 3 ) 2 , -C(CH 3 ) 2 CH 2 OH, -CH 2 CH 2 SO 2 CH 3 , -CH 2 OP(O)(OH) 2 , -CH 2 F, -CHF 2 , -CH 2 NH 2 , -CH 2 NHSO 2 CH 3 , -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 , -CF 3 , -CH 2 CF 3 , -CH 2 CHF 2 , -CH(CH 3 )CN, -C(CH 3 ) 2 CN, -CH 2 CN, -CO 2 H, -COCH 3 , -CO 2 CH 3 , -CO 2 C(CH 3 ) 3 , -COCH(OH)CH 3 , -CONH 2 , -CONHCH 3 , -CONHCH 2 CH 3 , -CONHCH(CH 3 ) 2 , -CON(CH 3 ) 2 , -C(CH 3 ) 2 CONH 2 , -NH 2 , -NHCH 3 , -N(CH 3 ) 2 , -NHCOCH 3 , -N(CH 3 )COCH 3 , -NHS(O) 2 CH 3 , -N(CH 3 )C(CH 3 ) 2 CONH 2 , -N(CH 3 )CH 2 CH 2 S(O) 2 CH 3 , -NO 2 , =O, -OH, -OCH 3 , -OCH 2 CH 3 , -OCH 2 CH 2 OCH 3 , -OCH 2 CH 2 OH, -OCH 2 CH 2 N(CH 3 ) 2 , -OP(O)(OH) 2 , -S(O) 2 N(CH 3 ) 2 , -SCH 3 , -S(O) 2 CH 3 , -S(O) 3 H, cyclopropyl, cyclobutyl, azetidinyl, oxetanyl, cyclopentyl, tetrahydrofuranyl, morpholinyl, piperidyl, piperazinyl, and tetrahydropyranyl. <EOS>